the market?
Dendreon Corp
NASDAQ: DNDN
3.99
-0.09
(-2.21%)
| Today's Open | $4.10 |
|---|---|
| Previous Close | $4.08 |
| Daily Range | $3.98 - $4.11 |
| 52-Week Range | $3.69 - $7.94 |
| Market Cap | $628.8M |
| P/E Ratio | -1.68 |
| Dividend (Yield) | $0.00 (0.0%) |
| Volume | 2,335,977 |
| Average Daily Volume | 4,581,523 |
| Current FY EPS | -$1.60 |
How do you think DNDN
will perform against the market?
Top DNDN Bull/Bear Pitches
zzlangerhans (< 20)
Submitted
August 5, 2011
Wow. I haven't followed Dendreon closely since I predicted incorrectly that their repeat phase III trial of Provenge would fail. I maintained some skepticism about the commercial potential of Provenge … More
DarthMaul09 (< 20)
Submitted
November 5, 2011
Medication formularies are more likely to contract as profit margins for insurance companies fall. Independent of how potentially beneficial a new drug may initially appear, there will be a slow acce … More
News & Commentary
One Person's Trash Is Another Person's Treasure Portfolio
A yearlong exercise intent on proving that value and contrarian investing can be incredibly successful.3 Reasons You Shouldn't Buy Stocks in Biotech
Wondering if you should buy stocks in biotech? Here are 3 reasons why you might want to take a pass.Why Progenics Is Poised to Plunge
Market-lagging returns could be written in this 2-star stock.Pre-Market Most Active for May 31, 2013 : BAC, NOK, SPIL, BBRY, AL, RDS/A, ING, DNDN, SIRI, NBG, OV
Pre-Market Most Active for May 31, 2013 : BAC, NOK, SPIL, BBRY, AL, RDS/A, ING, DNDN, SIRI, NBG, OVTI, FBThis Cancer Drug Developer Could Really Use a Partner
This company's lead drug will beef up your immune system to fight cancer, but it could sorely use a marketing partner to help drum up sales.One Person's Trash Is Another Person's Treasure Portfolio
A year-long exercise intent on proving that value and contrarian investing can be incredibly successful.Sector
Healthcare
Industry
Drugs
Dendreon Corp (DNDN) Description
A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. Website: http://www.dendreon.com/
CEO Rating by Glassdoor
More details for Dendreon Jobs
Dendreon reviews from employees
